Vantia Tops Up With £4 mill Series B To Pursue Nocturia And Dysmenorrhea
This article was originally published in The Pink Sheet Daily
Executive Summary
Novel products for nocturia and dysmenorrhea attract series B funding for U.K.'s Vantia.
You may also be interested in...
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. launched in August 2011 as a spin out of Vantia Therapeutics. KalVista acquired a portfolio of small-molecule plasma kallikrein inhibitors from Vantia's preclinical store. The compounds will be developed to treat diabetic macular edema, a condition that threatens the vision of up to a quarter of the world's 285 million diabetes sufferers.
U.K. Ophthalmology Spin-Out Raises £8m For DME Programs
SV Life Sciences and Novo AS support spin-out KalVista with £8m to advance preclinical DME programs.
U.K. Ophthalmology Spin-Out Raises £8m For DME Programs
SV Life Sciences and Novo AS support spin-out KalVista with £8m to advance preclinical DME programs.